title: [Interstitial brachytherapy of peri-orificial skin carcinomas on the face].
abstract: Purpose. - To analyse outcomes after interstitial brachytherapy of facial periorificial skin carcinomas. Patients and methods. - We performed a retrospective analysis of 97 skin carcinomas (88 basal cell carcinomas (BCCs), 9 squamous cell carcinomas (SCCs)) of the nose, periorbital areas and ears from 40 previously untreated patients (group 1) and 57 patients who had undergone surgery (group 2). The average dose was 55 Gy [50-65] in group 1 and 52 Gy [50-60] in group 2 (mean implantation times: 79 and 74 hours respectively). We calculated survival rates and assessed functional and cosmetic results de visu. Results. - Median age was 71 years [17-97]. There were 29 T1, 8 T2, 1 T3 and 2 Tx tumors in group 1. Tumors were<2 cm in group 2. Local control was 92.5% in group 1 and 88% in group 2 (median follow-up: 55 months [6-132]). Five-year disease-free survival was better in group 1 (91% [75-97]) than in group 2 (80% [62-90]), P=0.23. Of the 34 patients whose results were re-assessed, eight presented pruritus or epiphora. One group 2 patient had an impaired eyelid aperture. Cosmetic results were better in group 1 than in group 2, with respectively 72% (8/11) vs 52% (12/23) of good results and 28 (3/11) vs. 43% (10/23) of fair results. Conclusion. - Brachytherapy provided a high level of local control and good cosmetic results for facial periorificial skin carcinomas that pose problems of surgical reconstruction. Results were better for untreated tumors than for incompletely excised tumors or tumors recurring after surgery.
authors.affiliation: Service de radiothérapie, CRLCC Nantes-Atlantique, 44000 Nantes, France.
authors.forename: E
authors.initials: E
authors.lastname: Rio
authors.forename: E
authors.initials: E
authors.lastname: Bardet
authors.forename: C
authors.initials: C
authors.lastname: Ferron
authors.forename: P
authors.initials: P
authors.lastname: Peuvrel
authors.forename: S
authors.initials: S
authors.lastname: Supiot
authors.forename: L
authors.initials: L
authors.lastname: Campion
authors.forename: C
authors.initials: C
authors.lastname: Beauvillain De Montreuil
authors.forename: M-A
authors.initials: MA
authors.lastname: Mahe
authors.forename: B
authors.initials: B
authors.lastname: Dreno
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000379:methods; D002280:Basal Cell Carcinoma / Q000532:radiotherapy*; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D004428:Ear Neoplasms / Q000532:radiotherapy*; D004431:Ear, External; D005142:Eyelid Neoplasms / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009669:Nose Neoplasms / Q000532:radiotherapy*; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000532:radiotherapy*